Premier Diagnostics v. Invitae Corporation

2023 ME 1, 288 A.3d 791
Supreme Judicial Court of Maine·Decided January 5, 2023·No. Som-22-26·Published·Cited by 1 cases

Opinion

MAINE SUPREME JUDICIAL COURT Reporter of Decisions Decision: 2023 ME 1 Docket: Som-22-26 Argued: October 5, 2022 Decided: January 5, 2023

Panel: STANFILL, C.J., and MEAD, JABAR, HORTON, CONNORS, and LAWRENCE, JJ.

PREMIER DIAGNOSTICS

v.

INVITAE CORPORATION

STANFILL, C.J.

[¶1] Premier Diagnostics appeals from an order of the Superior Court (Somerset County, Mullen, C.J.) dismissing its complaint for lack of personal jurisdiction over the defendant, Invitae Corporation. Because we conclude that Maine has personal jurisdiction over Invitae in this case, we vacate the judgment of dismissal.

I. BACKGROUND

[¶2] The following facts, which we construe in Premier’s favor, are contained in the parties’ pleadings and affidavits. See Fore, LLC v. Benoit, 2012 ME 1, ¶ 10, 34 A.3d 1125.

[¶3] Premier is a Delaware limited liability company, and its principal place of business is in Madison, Maine. As such, Premier is a Maine resident.1 Kelly Hall is a member and the only employee of Premier; she also resides in Madison. A significant element of Premier’s business is to use Hall to introduce pharmacogenetic testing services (PGx testing) to healthcare organizations and match them with laboratories who provide PGx testing.

[¶4] Invitae is a Delaware corporation with its principal place of business in California. It is a leading national provider of medical genetic testing services. It asserts it is not registered to do business in Maine, has no registered agent in Maine, and does not own any real or personal property in Maine. Of its 2,555 employees, six are located in Maine and work from home. In 2020, Invitae made $1,194,409 in sales to customers in Maine, representing less than one-half of one percent of its total sales for that period. Premier does not argue that these contacts with Maine are sufficient, without more, to confer personal jurisdiction over Invitae.

1For purposes of personal jurisdiction, a limited liability company is a resident or citizen of the state under whose laws it is organized and of the state where it has its principal place of business. See Daimler AG v. Bauman, 571 U.S. 117, 137 (2014) (explaining that a corporation is “at home” in the state where it is incorporated and the state where it has its principal place of business); Frank v. PNK (Lake Charles) LLC, 947 F.3d 331, 337 n.10 (5th Cir. 2020) (noting that many courts apply the same “at home” test used for corporations to LLCs). Thus, Premier is a citizen of both Delaware and Maine.

[¶5] In June 2019, Hall was working with a healthcare system in Florida, Baptist Health (Baptist), to match it with a new PGx testing laboratory. Around the same time, Hall started networking with a PGx testing laboratory called Genelex. Hall corresponded with Genelex and its chief executive officer, Chris Howlett, for several months during 2019, discussing the benefits that Genelex could provide to her client, Baptist. After some time, the Genelex team represented to Hall that if she could broker a deal between Genelex and Baptist, she would be Genelex’s designated “point person” on the Baptist account. As the point person on the account, Hall would have a host of responsibilities, including onboarding, regular evaluation, monitoring, and consulting. Genelex formalized this representation in a letter of intent, emailed to Hall around August 21, 2019, offering to engage Premier as a consultant on various Genelex PGx accounts, including the Baptist account.

[¶6] In September and October 2019, Hall spent considerable time cultivating the relationship between Genelex and Baptist. Eventually, Baptist informed Hall that it had decided to partner with Genelex based on her recommendation and efforts. For the next six months, Hall worked nearly full time to finalize the Genelex-Baptist agreement.

[¶7] In January 2020, Howlett emailed Hall a proposed consulting services agreement (CSA) between Premier and Genelex; the CSA included a statement of work for the Baptist account. Hall signed and returned the agreement about a month later. Thereafter, Hall continued to work diligently to finalize the deal between Baptist and Genelex. Hall did so at Genelex’s request, even though Genelex had not yet signed the CSA.

[¶8] In March 2020, with the CSA still only partially executed, Invitae announced that it had entered into an agreement to acquire Genelex.2 For purposes of this appeal, Invitae concedes that Genelex was thereafter acting as its agent. On March 11, 2020, Hall emailed Howlett from her office in Maine to ask whether the acquisition would impact their pending contract and whether Premier should “explore relationships with other PGx testing labs.” In response, Howlett emailed Hall a fully executed copy of the CSA and informed her “that Invitae had confirmed that its acquisition of Genelex would have no impact on the relationship, or contract, between Genelex and Premier Diagnostics.”

[¶9] Baptist and Genelex then executed an agreement under which Genelex would provide PGx testing for Baptist. Baptist’s decision to move

2 Invitae officially acquired a one hundred percent ownership interest in Genelex on April 1, 2020.

forward with the deal was “a direct result” of Hall’s efforts on behalf of Premier and Genelex’s “assurances that the Invitae transaction would have no impact on the relationship with Premier.” Thereafter, Hall contacted Howlett multiple times to determine when her onboarding and orientation would occur as provided in the CSA. Howlett responded that his time working with Premier was limited by the Invitae acquisition, and her onboarding could not be scheduled. Genelex never onboarded Hall.

[¶10] On May 27, 2020, Hall learned from Baptist that Invitae was excluding her from onboarding meetings with Baptist by instructing Genelex to hold the meetings using Invitae employees instead of Hall and Premier. The next day, Invitae instructed Genelex to terminate the CSA.

[¶11] The complaint alleges that Invitae, through Genelex, fraudulently misrepresented to Hall that the acquisition by Invitae would not impact Premier and Genelex’s agreements; fraudulently induced Premier to continue to work to finalize the Baptist deal; instructed Genelex to hold onboarding meetings with Baptist and exclude Premier from that process; and pressured and instructed Genelex to terminate the CSA after Baptist had finalized the agreement with Genelex. Premier alleges it suffered significant economic damages as a result of Invitae’s conduct.

[¶12] Based on these allegations, Premier asserted a claim of tortious interference with contractual and advantageous economic relations against Invitae, as Genelex’s principal.3 Invitae moved to dismiss the complaint on the ground that Maine lacked personal jurisdiction over Invitae. The court agreed and dismissed the complaint.4 The court's order was based on the pleadings, exhibits, and affidavits only; it did not hold an evidentiary hearing. Premier filed a timely appeal.

II. DISCUSSION

[¶13] “The term ‘personal jurisdiction’ refers to a court’s power to bring a person into its adjudicative process.” Fore, 2012 ME 1, ¶ 5, 34 A.3d 1125 (alteration and quotation marks omitted). “We review de novo whether personal jurisdiction exists.” Id.

[¶14] Maine’s long-arm statute “shall be applied so as to assert jurisdiction over nonresident defendants to the fullest extent permitted by the

Free access — add to your briefcase to read the full text and ask questions with AI

Premier Diagnostics v. Invitae Corporation, 2023 ME 1, 288 A.3d 791 (Me. 2023).

2023 ME 1 (Premier Diagnostics v. Invitae Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

John R. Luongo v. Micharel A. Luongo Jr.
2023 ME 75 (Supreme Judicial Court of Maine, 2023)